You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: GPB Scientific, Inc. Topic: 101
ABSTRACT The goal of this Fast-Track STTR project is to develop a Deterministic Lateral Displacement (DLD) microfluidic device that can enrich white blood cells (WBCs) from a typical leukapheresis unit in 1 hr, for use in manufacturing cancer cellular immunotherapy. Chimeric antigen receptor T cell (CAR-T) therapy has been recommended for FDA approval to treat relapsed or refractory pediatric and ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: PRAXIS, INC. Topic: 104
Project Summary The primary goal of this proposal is to develop, implement, and evaluate an online module to improve obstetric providers’ knowledge, attitudes, and practices regarding perinatal mood and anxiety disorders. Upwards of 1 in 5 women suffer from perinatal mood and anxiety disorders. Left untreated, they have deleterious effects on maternal and birth outcomes, infant attachment, and c ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: SOLANO PHARMACEUTICALS, INC. Topic: NINDS
DESCRIPTION (provided by applicant): Oxidative damage to mitochondrial is a major source of toxicity in diseases such as Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases (HD). Mitochondria are energy powerhouses of the cell, and decline in their function by oxidative damage is a common feature among neurodegenerative diseases. Despite years of effort, however, generic ...STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
SBC: MICROBIOTIX, INC. Topic: N/A
DESCRIPTION (provided by applicant): The increasing prevalence of antibiotic-resistant strains of bacterial pathogens represents a major unmet medical need. Naturally occuring or intentionally engineered drug-resistance in biothreat agents is also a serious risk for biodefense. The development of new antibiotics against unexploited targets with novel mechanisms of action is a vital part of the sol ...STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
SBC: Op-T-Mune, Inc Topic: NIAID
Type 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: ROBIN MEDICAL INC Topic: NIMH
DESCRIPTION (provided by applicant): The long term objective of the project is to develop a new motion robust magnetic resonance imaging (MRI) technology. Magnetic resonance imaging is a powerful tool that aids in the diagnosis of individual subjects, guides their clinical care, ad provides insights into the mechanisms of normal and atypical development. The characterization of mental health disor ...STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
SBC: OASIS PHARMACEUTICALS, LLC Topic: NIDDK
DESCRIPTION provided by applicant Non alcoholic steatohepatitis NASH is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates NASH is frequently associated with other common metabolic abnormalities such as insulin resistance and visceral obesity Liver transplantation is curren ...STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
SBC: PROFUSA, INC. Topic: NHLBI
DESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: GAMMA MEDICA-IDEAS, INC. Topic: N/A
DESCRIPTION (provided by applicant): The focus of this proposal is the development of a novel in-vivo imaging device (Molecular Breast Imaging system) that incorporates a clinical validation experiment and a limited pilot and a clinical feasibility evaluation for pre-clinical and clinical studies. Our primary intent is to facilitate the proof of feasibility of this novel imaging device for early ...STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
SBC: TUNITAS THERAPEUTICS, INC. Topic: NIAID
DESCRIPTION (provided by applicant): The overall goal of this Phase 2 STTR is to develop and commercialize a novel approach for allergen specific immunotherapy as a treatment for severe food allergy. Currently treatment to prevent severe food reactions isa major unmet need. There is no effective therapy, the only treatment being strict avoidance and emergency measures should an exposure occur. Th ...STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health